Aurobindo Pharma Limited has informed the Exchange regarding a press release dated October 03, 2026, titled "Aurobindo Pharma receives USFDA Final Approval for Perampanel Tablets, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg".
Filed with NSE ·
6ix hasn’t read this filing yet.
View original source (NSE India)Company analysis
Earlier from Aurobindo Pharma
- Aurobindo Pharma Ltd Press Release Sep 30 2026
- Aurobindo Pharma Limited has informed the Exchange regarding a press release dated September 30, 2026, titled "Acrotech Biopharma Launches ADQUEY in the U.S. and Establishes Dedicated Dermatology Business".
- Aurobindo Pharma Ltd Press Release Sep 15 2026
- Aurobindo Pharma Ltd Press Release Aug 31 2026